利德曼：预计2025年全年净亏损1500万元—2800万元

Core Viewpoint - Lidman is expected to report a net loss attributable to shareholders of the listed company ranging from 15 million to 28 million yuan for the year 2025, indicating a challenging financial outlook for the company [1] Financial Performance - The company anticipates a net loss of 24 million to 37 million yuan when excluding non-recurring gains and losses for the year 2025 [1] - The expected impact of non-recurring gains and losses on net profit for the current period is approximately 9 million yuan, primarily from government subsidies and fair value changes [1] - In the previous year, the impact of non-recurring gains and losses on net profit was 22.37 million yuan [1] Industry Context - The company's main business revenue and gross margin for diagnostic reagent products have declined year-on-year due to factors such as the expansion of domestic diagnostic reagent centralized procurement, further implementation of DRG/DIP policies, and intensified industry competition [1]